$14.85
1.03% today
Nasdaq, Feb 28, 05:21 pm CET
ISIN
US67080M1036
Symbol
NRIX
Sector
Industry

Nurix Therapeutics Inc Stock price

$15.00
-4.81 24.28% 1M
-9.59 39.00% 6M
-3.84 20.38% YTD
+3.12 26.26% 1Y
-1.17 7.24% 3Y
-4.01 21.09% 5Y
-4.01 21.09% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-2.06 12.08%
ISIN
US67080M1036
Symbol
NRIX
Sector
Industry

Key metrics

Market capitalization $1.14b
Enterprise Value $557.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 10.21
P/S ratio (TTM) P/S ratio 20.87
P/B ratio (TTM) P/B ratio 2.16
Revenue growth (TTM) Revenue growth -29.15%
Revenue (TTM) Revenue $54.55m
EBIT (operating result TTM) EBIT $-213.03m
Free Cash Flow (TTM) Free Cash Flow $-181.86m
Cash position $609.58m
EPS (TTM) EPS $-2.89
P/E forward negative
P/S forward 19.29
EV/Sales forward 9.44
Short interest 15.40%
Show more

Is Nurix Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Nurix Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Nurix Therapeutics Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Nurix Therapeutics Inc forecast:

Buy
94%
Hold
6%

Financial data from Nurix Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Nov '24
+/-
%
55 55
29% 29%
100%
- Direct Costs 16 16
20% 20%
30%
38 38
40% 40%
70%
- Selling and Administrative Expenses 22 22
3% 3%
41%
- Research and Development Expense 212 212
17% 17%
389%
-197 -197
39% 39%
-360%
- Depreciation and Amortization 16 16
20% 20%
30%
EBIT (Operating Income) EBIT -213 -213
37% 37%
-391%
Net Profit -194 -194
34% 34%
-355%

In millions USD.

Don't miss a Thing! We will send you all news about Nurix Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nurix Therapeutics Inc Stock News

Neutral
GlobeNewsWire
14 days ago
SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on Febr...
Neutral
GlobeNewsWire
24 days ago
SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that Arthur ...
Neutral
GlobeNewsWire
about one month ago
R eported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66 th American Society of Hematology Annual Meeting
More Nurix Therapeutics Inc News

Company Profile

Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Head office United States
CEO Arthur Sands
Employees 286
Founded 2009
Website www.nurixtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today